Our MD Mr. Anand Jha was invited by Medtech Innovator to speak with a cohort of Medtech companies – startups as well as scales-up firms – to talk about the considerations related to pricing, healtheconomics, evidence development related to medical devices. Together with his co-speaker Jordan Chase from Cepheid, the following topics were covered in the session:
- Evolving trends in the reimbursement environment in Asia-Pacific and the US
- When should a medtech startup begin thinking about its health economic narrative & reimbursement strategy? When should the startup consider appointing an expert for advice?
- What should be the market launch priorities for a medtech start up?
- The three key components of the US reimbursement system – coding, coverage, payment?
- CPT codes – What are they? Why are they important? What other types of codes exist? Is it always better for a startup with a new technology to try to use an existing code?
- How does a non-US startup engage with CMS? What are some other examples of public and privatepayors in the US that companies should be aware of?
- What are some examples of payor organizations in APAC and how should companies engage with payors in APAC?
- Group purchasing in APAC: How extensive is the practice; in which markets? Implications for smaller companies and startups?
- What is the typical process of engaging with a payor in the US, and how long does the process typically take e.g. from first discussion to reimbursement.
- Health Technology Assessment VS. Value Based Healthcare – How are they related? What does a medtech startup need to know?
- How does a startup know what evidence is required to satisfy the payers? What are some of the differences between developed and less developed markets?
- What are some of the most common pitfalls made by early and mid-stage companies in defining their value proposition, and what advice can you offer to avoid these?
Full recording available at https://www.linkedin.com/company/medtech-innovator-apac/
